Hypersomnolence idiopathic. Medical search. Web

Disorders characterized by hypersomnolence during normal waking hours that may impair cognitive functioning. Subtypes include primary hypersomnia disorders (e.g., IDIOPATHIC HYPERSOMNOLENCE; NARCOLEPSY; and KLEINE-LEVIN SYNDROME) and secondary hypersomnia disorders where excessive somnolence can be attributed to a known cause (e.g., drug affect, MENTAL DISORDERS, and SLEEP APNEA SYNDROME). (From J Neurol Sci 1998 Jan 8;153(2):192-202; Thorpy, Principles and Practice of Sleep Medicine, 2nd ed, p320)

A sleep disorder of central nervous system origin characterized by prolonged nocturnal sleep and periods of daytime drowsiness. Affected individuals experience difficulty with awakening in the morning and may have associated sleep drunkenness, automatic behaviors, and memory disturbances. This condition differs from narcolepsy in that daytime sleep periods are longer, there is no association with CATAPLEXY, and the multiple sleep latency onset test does not record sleep-onset rapid eye movement sleep. (From Chokroverty, Sleep Disorders Medicine, 1994, pp319-20; Psychiatry Clin Neurosci 1998 Apr:52(2):125-129)

A state in which there is an enhanced potential for sensitivity and an efficient responsiveness to external stimuli.

A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.

An appreciable lateral deviation in the normally straight vertical line of the spine. (Dorland, 27th ed)

Arthritis of children, with onset before 16 years of age. The terms juvenile rheumatoid arthritis (JRA) and juvenile idiopathic arthritis (JIA) refer to classification systems for chronic arthritis in children. Only one subtype of juvenile arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent.

Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.

A group of interstitial lung diseases with no known etiology. There are several entities with varying patterns of inflammation and fibrosis. They are classified by their distinct clinical-radiological-pathological features and prognosis. They include IDIOPATHIC PULMONARY FIBROSIS; CRYPTOGENIC ORGANIZING PNEUMONIA; and others.

A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.

CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia. (1/15)

We measured cerebrospinal fluid (CSF) hypocretin-1 levels in 11 patients with narcolepsy-cataplexy, five with narcolepsy without cataplexy and 12 with idiopathic hypersomnia (IHS). All patients were Japanese. As reported in Caucasian patients, undetectable or very low hypocretin-1 levels were observed in most (9 out of 11) Japanese narcolepsy--cataplexy patients. Our hypocretin-deficient narcoleptics included three prepubertal cases within few months after the disease onset. All nine hypocretin-deficient patients were human leuckocyte antigen (HLA) DR2 positive, while two who had normal CSF hypocretin-1 levels were HLA DR2 negative. In contrast, none of the narcolepsy without cataplexy and IHS subjects had undetectable low levels. Low CSF hypocretin-1 is therefore very specific for HLA DR2 positive narcolepsy-cataplexy, and the deficiency is likely to be established at the early stage of the disease. (+info)

Psychiatric aspects of organic sleep disorders. (2/15)

In recent years, a number of studies have attempted to characterize psychological disturbances related to various sleep disorders. The objective of this type of research is to investigate the possibility that psychopathology may represent an etiological factor, a complication, and/or a target for treatment. In addition, disordered sleep can present itself in a complex and atypical fashion in which the primary sleep-related component may not be immediately apparent. This article reviews the evidence for a relationship between organic sleep disorders and psychiatric morbidity. Generally, it can be concluded that organic sleep disorders have a profound negative impact on most domains of health-related quality of life. Results for the sleep disorders that have been studied (narcolepsy idiopathic hypersomnia, sleep apnea/hypopnea syndrome, restless legs syndrome, periodic limb movement disorder, and circadian sleep disorders) show strong evidence for an association with mood disorders. After treatment, depression scores may or may not improve to the level of population norms, suggesting that this relationship is more complex than one of mere cause and effect. (+info)

Hypersomnia. (3/15)

Hypersomnia, a complaint of excessive daytime sleep or sleepiness, affects 4% to 6% of the population, with an impact on the everyday life of the patient Methodological tools to explore sleep and wakefulness (interview, questionnaires, sleep diary, polysomnography, Multiple Sleep Latency Test, Maintenance of Wakefulness Test) and psychomotor tests (for example, psychomotor vigilance task and Oxford Sleep Resistance or Osler Test) help distinguish between the causes of hypersomnia. In this article, the causes of hypersomnia are detailed following the conventional classification of hypersomnic syndromes: narcolepsy, idiopathic hypersomnia, recurrent hypersomnia, insufficient sleep syndrome, medication- and toxin-dependent sleepiness, hypersomnia associated with psychiatric disorders, hypersomnia associated with neurological disorders, posttraumatic hypersomnia, infection (with a special emphasis on the differences between bacterial and viral diseases compared with parasitic diseases, such as sleeping sickness) and hypersomnia, hypersomnia associated with metabolic or endocrine diseases, breathing-related sleep disorders and sleep apnea syndromes, and periodic limb movements in sleep. (+info)

CSF hypocretin-1 levels and clinical profiles in narcolepsy and idiopathic CNS hypersomnia in Norway. (4/15)

OBJECTIVE: To evaluate the relationship between CSF hypocretin-1 levels and clinical profiles in narcolepsy and CNS hypersomnia in Norwegian patients. METHOD: CSF hypocretin-1 was measured by a sensitive radioimmunoassay in 47 patients with narcolepsy with cataplexy, 7 with narcolepsy without cataplexy, 10 with idiopathic CNS hypersomnia, and a control group. RESULTS: Low hypocretin-1 values were found in 72% of the HLA DQB1*0602 positive patients with narcolepsy and cataplexy. Patients with low CSF hypocretin-1 levels reported more extensive muscular involvement during cataplectic attacks than patients with normal levels. Hypnagogic hallucinations and sleep paralysis occurred more frequently in patients with cataplexy than in the other patient groups, but with no correlation to hypocretin-1 levels. CONCLUSION: About three quarters of the HLA DQB1*0602 positive patients with narcolepsy and cataplexy had low CSF hypocretin-1 values, and appear to form a distinct clinical entity. Narcolepsy without cataplexy could not be distinguished from idiopathic CNS hypersomnia by clinical symptoms or biochemical findings. (+info)

Idiopathic hypersomnia: a study of 77 cases. (5/15)

STUDY OBJECTIVES: To review the clinical and polysomnographic characteristics of idiopathic hypersomnia as well as the long-term response to treatment. SETTING: The Respiratory Support and Sleep Centre at Papworth Hospital, Cambridge, UK. PATIENTS AND DESIGN: A large database of more than 6000 patients with sleep disorders was reviewed. A retrospective study of the clinical and polysomnographic characteristics of 77 patients with idiopathic hypersomnia was performed. Comparison with a similar group of patients with narcolepsy was performed. The response to drug treatment was assessed in 61 patients over a mean follow-up of 3.8 years. MEASUREMENTS AND RESULTS: Idiopathic hypersomnia was 60% as prevalent as narcolepsy. Comparison with a similar group of patients with narcolepsy showed that those with idiopathic hypersomnia were more likely to have prolonged unrefreshing daytime naps, a positive family history, increased slow-wave sleep, and a longer sleep latency on the Multiple Sleep Latency Test. The results of the Multiple Sleep Latency Test were not helpful in predicting disease severity or treatment response. The clinical features were heterogeneous and of variable severity. The majority of patients with idiopathic hypersomnia had symptoms that remained stable over many years, but 11% had spontaneous remission, which was never seen in narcolepsy. Two thirds of patients with idiopathic hypersomnolence had a sustained improvement in daytime somnolence with medication, although a third needed high doses or combinations of drugs. CONCLUSIONS: Idiopathic hypersomnolence has characteristic clinical and polysomnographic features but the prolonged latency on the Multiple Sleep Latency Test raises doubt about the validity of this test within the current diagnostic criteria. The disease often responds well to treatment and a substantial minority of patients appear to spontaneously improve. (+info)

Prevalence of the HLA-DQB1*0602 allele in narcolepsy and idiopathic hypersomnia patients seen at a sleep disorders outpatient unit in Sao Paulo. (6/15)

(+info)

Idiopathic hypersomnia with and without long sleep time: a controlled series of 75 patients. (7/15)

OBJECTIVE: To characterize the clinical, psychological, and sleep pattern of idiopathic hypersomnia with and without long sleep time, and provide normative values for 24-hour polysomnography. SETTING: University Hospital. DESIGN: Controlled, prospective cohort. PARTICIPANTS: 75 consecutive patients (aged 34 +/- 12 y) with idiopathic hypersomnia and 30 healthy matched controls. INTERVENTION: Patients and controls underwent during 48 hours a face-to-face interview, questionnaires, human leukocyte antigen genotype, a night polysomnography and multiple sleep latency test (MSLT), followed by 24-h ad libitum sleep monitoring. RESULTS: Hypersomniacs had more fatigue, higher anxiety and depression scores, and more frequent hypnagogic hallucinations (24%), sleep paralysis (28%), sleep drunkenness (36%), and unrefreshing naps (46%) than controls. They were more frequently evening types. DQB1*0602 genotype was similarly found in hypersomniacs (24.2%) and controls (19.2%). Hypersomniacs had more frequent slow wave sleep after 06:00 than controls. During 24-h polysomnography, the 95% confidence interval for total sleep time was 493-558 min in controls, versus 672-718 min in hypersomniacs. There were 40 hypersomniacs with and 35 hypersomniacs without long ( > 600 min) sleep time. The hypersomniacs with long sleep time were younger (29 +/- 10 vs 40 +/- 13 y, P = 0.0002), slimmer (body mass index: 26 +/- 5 vs 23 +/- 4 kg/m2; P = 0.005), and had lower Horne-Ostberg scores and higher sleep efficiencies than those without long sleep time. MSLT latencies were normal (> 8 min) in 71% hypersomniacs with long sleep time. CONCLUSIONS: Hypersomnia, especially with long sleep time, is frequently associated with evening chronotype and young age. It is inadequately diagnosed using MSLT. (+info)

Body mass index-independent metabolic alterations in narcolepsy with cataplexy. (8/15)

STUDY OBJECTIVES: To contribute to the anthropometric and metabolic phenotyping of orexin-A-deficient narcoleptic patients, and to explore a possible risk of their developing a metabolic syndrome. DESIGN: We performed a cross-sectional study comparing metabolic alterations in patients with narcolepsy with cataplexy (NC) and patients with idiopathic hypersomnia without long sleep time. SETTING: University hospital. PATIENTS: Fourteen patients with narcolepsy with cataplexy and 14 sex and age-matched patients with idiopathic hypersomnia without long sleep time. INTERVENTIONS: N/A. MEASUREMENTS AND RESULTS: Metabolic parameters were evaluated by measuring body mass index (BMI), waist circumference (also with abdominal computed tomography), blood pressure, and daily calorie intake (3-day diary). Chronotypes were assessed through the morningness-eveningness questionnaire. Lumbar puncture for cerebrospinal fluid orexin-A determination and HLA typing were performed. Patients with narcolepsy with cataplexy (all HLA DQB1*0602 positive and with cerebrospinal fluid orexin-A levels < 110 pg/mL) had a higher BMI and BMI-independent metabolic alterations, namely waist circumference, high-density lipoprotein cholesterol, and glucose/insulin ratio (an insulin resistance index), with respect to patients with idiopathic hypersomnia without long sleep time (cerebrospinal fluid orexin-A levels > 300 pg/mL). Despite lower daily food intake, patients with narcolepsy with cataplexy displayed significant alterations in metabolic parameters resulting in a diagnosis of metabolic syndrome in more than half the cases. CONCLUSIONS: BMI-independent metabolic alterations and the relative hypophagia of patients with narcolepsy with cataplexy, as compared with patients with idiopathic hypersomnia without long sleep time, suggest that orexin-A influences the etiology of this phenotype. Moreover, considering that these dysmetabolic alterations are present from a young age, a careful metabolic follow-up of patients diagnosed with narcolepsy with cataplexy is mandatory. (+info)

Disorders of excessive somnolence (DES) are a group of medical conditions characterized by an increased tendency to fall asleep or experience excessive daytime sleepiness (EDS), despite having adequate opportunity and circumstances for sleep. These disorders are typically classified as central disorders of hypersomnolence according to the International Classification of Sleep Disorders (ICSD-3).

The most common DES is narcolepsy, a chronic neurological disorder caused by the brain's inability to regulate sleep-wake cycles normally. Other DES include idiopathic hypersomnia, Kleine-Levin syndrome, and recurrent hypersomnia. These disorders can significantly impact an individual's daily functioning, quality of life, and overall health.

Narcolepsy is further divided into two types: narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). NT1 is characterized by the presence of cataplexy, a sudden loss of muscle tone triggered by strong emotions, while NT2 does not include cataplexy. Both types of narcolepsy involve excessive daytime sleepiness, sleep paralysis, hypnagogic/hypnopompic hallucinations, and fragmented nighttime sleep.

Idiopathic hypersomnia is a DES without the presence of REM-related symptoms like cataplexy or sleep paralysis. Individuals with idiopathic hypersomnia experience excessive daytime sleepiness and prolonged nighttime sleep, often lasting 10 to 14 hours, but do not feel refreshed upon waking.

Kleine-Levin syndrome is a rare DES characterized by recurrent episodes of excessive sleepiness, often accompanied by cognitive impairment, altered perception, hyperphagia (excessive eating), and hypersexuality during the episodes. These episodes can last days to weeks and typically occur multiple times per year.

Recurrent hypersomnia is another rare DES with recurring episodes of excessive sleepiness lasting for several days, followed by a period of normal or reduced sleepiness. The episodes are not as predictable or consistent as those seen in Kleine-Levin syndrome.

Treatment for DES typically involves pharmacological interventions to manage symptoms and improve daytime alertness. Modafinil, armodafinil, and traditional stimulants like amphetamine salts are commonly used to treat excessive daytime sleepiness. Additionally, antidepressants may be prescribed to manage REM-related symptoms like cataplexy or sleep paralysis. Non-pharmacological interventions, such as scheduled napping and good sleep hygiene practices, can also help improve symptoms.

Idiopathic hypersomnolence is a type of central disorder of hypersomnolence, which is characterized by excessive daytime sleepiness (EDS) that isn't caused by another known medical condition or lifestyle factor. "Idiopathic" means that the cause of the condition is unknown.

In idiopathic hypersomnolence, individuals experience prolonged nighttime sleep and recurrent episodes of daytime sleep that can last for several hours, causing significant impairment in their daily functioning. Despite getting adequate or even prolonged periods of sleep, they continue to feel excessive sleepiness during the day.

Other symptoms associated with idiopathic hypersomnolence may include difficulty waking up from sleep, automatic behavior (performing actions without conscious awareness), cognitive impairment, and mood changes. The exact cause of this condition remains unclear, but it is thought to involve dysfunction in the brain's sleep-wake regulation mechanisms.

Wakefulness is a state of consciousness in which an individual is alert and aware of their surroundings. It is characterized by the ability to perceive, process, and respond to stimuli in a purposeful manner. In a medical context, wakefulness is often assessed using measures such as the electroencephalogram (EEG) to evaluate brain activity patterns associated with consciousness.

Wakefulness is regulated by several interconnected neural networks that promote arousal and attention. These networks include the ascending reticular activating system (ARAS), which consists of a group of neurons located in the brainstem that project to the thalamus and cerebral cortex, as well as other regions involved in regulating arousal and attention, such as the basal forebrain and hypothalamus.

Disorders of wakefulness can result from various underlying conditions, including neurological disorders, sleep disorders, medication side effects, or other medical conditions that affect brain function. Examples of such disorders include narcolepsy, insomnia, hypersomnia, and various forms of encephalopathy or brain injury.

Idiopathic Pulmonary Fibrosis (IPF) is a specific type of chronic, progressive, and irreversible fibrotic lung disease of unknown cause, characterized by scarring (fibrosis) in the lungs that thickens and stiffens the lining of the air sacs (alveoli). This makes it increasingly difficult for the lungs to transfer oxygen into the bloodstream, leading to shortness of breath, cough, decreased exercise tolerance, and, eventually, respiratory failure.

The term "idiopathic" means that the cause of the disease is unknown. The diagnosis of IPF requires a combination of clinical, radiological, and pathological findings, excluding other known causes of pulmonary fibrosis. It primarily affects middle-aged to older adults, with a higher prevalence in men than women.

The progression of IPF varies from person to person, but the prognosis is generally poor, with a median survival time of 3-5 years after diagnosis. Currently, there are two FDA-approved medications for the treatment of IPF (nintedanib and pirfenidone), which can help slow down disease progression but do not cure the condition. Lung transplantation remains an option for select patients with advanced IPF.

Scoliosis is a medical condition characterized by an abnormal lateral curvature of the spine, which most often occurs in the thoracic or lumbar regions. The curvature can be "C" or "S" shaped and may also include rotation of the vertebrae. Mild scoliosis doesn't typically cause problems, but severe cases can interfere with breathing and other bodily functions.

The exact cause of most scoliosis is unknown, but it may be related to genetic factors. It often develops in the pre-teen or teenage years, particularly in girls, and is more commonly found in individuals with certain neuromuscular disorders such as cerebral palsy and muscular dystrophy.

Treatment for scoliosis depends on the severity of the curve, its location, and the age and expected growth of the individual. Mild cases may only require regular monitoring to ensure the curve doesn't worsen. More severe cases may require bracing or surgery to correct the curvature and prevent it from getting worse.

Juvenile arthritis (JA) is a term used to describe a group of autoimmune and inflammatory disorders that can affect children aged 16 or younger. In JA, the immune system mistakenly attacks the body's own tissues, causing inflammation in the joints, which can lead to pain, swelling, stiffness, and damage over time.

There are several types of juvenile arthritis, including:

1. Juvenile Idiopathic Arthritis (JIA): This is the most common form of JA, and it includes several subtypes that are classified based on the number of joints affected and the presence or absence of certain symptoms.
2. Juvenile Systemic Lupus Erythematosus (JSLE): This is a type of lupus that affects children, and it can cause inflammation in various parts of the body, including the joints, skin, kidneys, and lungs.
3. Juvenile Dermatomyositis (JDM): This is a rare autoimmune disorder that causes inflammation of the blood vessels, leading to muscle weakness, skin rashes, and joint pain.
4. Juvenile Scleroderma: This is a group of disorders that cause hardening and tightening of the skin and connective tissues, which can also affect the joints.
5. Juvenile Psoriatic Arthritis (JPsA): This is a type of arthritis that affects children who have psoriasis, a chronic skin condition. JPsA can cause inflammation in the joints and skin.

The causes of juvenile arthritis are not fully understood, but it is believed to involve a combination of genetic and environmental factors. There is no cure for JA, but treatments such as medication, physical therapy, and lifestyle changes can help manage the symptoms and prevent long-term complications.

Idiopathic Thrombocytopenic Purpura (ITP) is a medical condition characterized by a low platelet count (thrombocytopenia) in the blood without an identifiable cause. Platelets are small blood cells that help your body form clots to stop bleeding. When you don't have enough platelets, you may bleed excessively or spontaneously, causing purpura, which refers to purple-colored spots on the skin that result from bleeding under the skin.

In ITP, the immune system mistakenly attacks and destroys platelets, leading to their decreased levels in the blood. This condition can occur at any age but is more common in children following a viral infection, and in adults after the age of 30-40 years. Symptoms may include easy or excessive bruising, prolonged bleeding from cuts, spontaneous bleeding from the gums or nose, blood blisters, and small red or purple spots on the skin (petechiae).

Depending on the severity of thrombocytopenia and the presence of bleeding symptoms, ITP treatment may include observation, corticosteroids, intravenous immunoglobulin (IVIG), or other medications that modify the immune system's response. In severe cases or when other treatments are ineffective, surgical removal of the spleen (splenectomy) might be considered.

Idiopathic interstitial pneumonias (IIPs) are a group of rare lung diseases with no known cause, characterized by inflammation and scarring (fibrosis) of the lung tissue. The term "idiopathic" means that the cause is unknown, and "interstitial" refers to the spaces between the air sacs in the lungs where the inflammation and scarring occur.

IIPs are classified into several subtypes based on their clinical, radiological, and pathological features. These include:

1. Idiopathic Pulmonary Fibrosis (IPF): This is the most common and aggressive form of IIP, characterized by progressive scarring of the lung tissue, which leads to difficulty breathing and decreased lung function over time.
2. Nonspecific Interstitial Pneumonia (NSIP): This subtype is characterized by varying degrees of inflammation and fibrosis in the lung tissue. NSIP can be idiopathic or associated with connective tissue diseases.
3. Respiratory Bronchiolitis-Interstitial Lung Disease (RB-ILD): This subtype primarily affects smokers and is characterized by inflammation of the small airways and surrounding lung tissue.
4. Desquamative Interstitial Pneumonia (DIP): This subtype is also more common in smokers and is characterized by accumulation of pigmented macrophages in the lung tissue.
5. Cryptogenic Organizing Pneumonia (COP): This subtype is characterized by the formation of fibrous masses in the small airways and alveoli, leading to cough and shortness of breath.
6. Acute Interstitial Pneumonia (AIP)/Acute Respiratory Distress Syndrome (ARDS): This subtype is a severe form of IIP that can rapidly progress to respiratory failure and requires immediate medical attention.

The diagnosis of IIPs typically involves a combination of clinical evaluation, imaging studies, and lung biopsy. Treatment options may include corticosteroids, immunosuppressive medications, and oxygen therapy, depending on the severity and subtype of the disease.

Pulmonary fibrosis is a specific type of lung disease that results from the thickening and scarring of the lung tissues, particularly those in the alveoli (air sacs) and interstitium (the space around the air sacs). This scarring makes it harder for the lungs to properly expand and transfer oxygen into the bloodstream, leading to symptoms such as shortness of breath, coughing, fatigue, and eventually respiratory failure. The exact cause of pulmonary fibrosis can vary, with some cases being idiopathic (without a known cause) or related to environmental factors, medications, medical conditions, or genetic predisposition.

News about Hypersomnolence Australia, Idiopathic Hypersomnia and related subjects ... Catch up on Idiopathic Hypersomnia & Narcolepsy NEWS - includes all the latest in AUSTRALIAN RESEARCH NEWS! ... Michelle Chadwick is the founder of Hypersomnolence Australia (HA), the worlds first not for profit organisation to be ... The main symptom of Idiopathic Hypersomnia (IH) is excessive sleep and extreme daytime sleepiness. Despite having extraordinary ...

https://www.hypersomnolenceaustralia.org.au/news

Narcolepsy and Idiopathic Hypersomnolence Bookmark [insert headline / title here]. Narcolepsy and Idiopathic Hypersomnolence ... are disorders of excessive sleep (hypersomnolence). Both of these problems may be evaluated with a polysomnogram to rule out ...

https://www.archildrens.org/programs-and-services/sleep-disorders

Choo KL, Guilleminault C (March 1998). "Narcolepsy and idiopathic hypersomnolence". Clinics in Chest Medicine. 19 (1): 169-81. ... For idiopathic hypersomnia, patients typically experience sleep inertia and are unrefreshed after napping. How long and when a ...

https://en.wikipedia.org/wiki/Nap

Severe idiopathic hypersomnolence is a disabling problem that often leads to permanent unemployment and responds poorly to ... Therapy for idiopathic hypersomnolence involves maintaining the patient on daytime stimulants. The drug dose is titrated so ... 3, 83] Moreover, because the underlying cause of idiopathic hypersomnolence is unknown, treatment remains symptomatic in nature ... Sleepiness in nonnarcoleptic, non-sleep apneic EDS patients: the idiopathic CNS hypersomnolence. Sleep. 1982. 5 Suppl 2:S175-81 ...

https://emedicine.medscape.com/article/291699-treatment

Primary hypersomnia, idiopathic hypersomnia (ICSD-3), and hypersomnolence disorder (DSM-5) refer to a central disorder of ... Hypersomnolence is an idiopathic disorder. Although head injury or viral infections can cause a disorder resembling primary ... Sleepiness in nonnarcoleptic, non-sleep apneic EDS patients: the idiopathic CNS hypersomnolence. Sleep. 1982. 5 Suppl 2:S175-81 ... The specific DSM-5 criteria for hypersomnolence disorder are as follows:. * Self-reported excessive sleepiness (hypersomnolence ...

https://emedicine.medscape.com/article/291699-overview

Mark Wu specializes in sleep disorders and has a particular interest in narcolepsy, idiopathic hypersomnolence... ...

https://www.hopkinsmedicine.org/profiles/search?specialties=Neurology&Page=10

Central Causes of Hypersomnolence (narcolepsy, idiopathic hypersomnia). Hypersomnolence. Like narcolepsy, hypersomnolence (also ... Idiopathic Hypersomnia. Idiopathic hypersomnia is an uncommon disorder causing excessive sleepiness during the day even after a ... Patients experience difficulty in waking (either in the morning or at the end of nap periods during the day). Idiopathic simply ... Unlike narcolepsy, idiopathic hypersomnia does not have rapid occurrence of dream sleep during daytime napping. ...

https://blueskyneurology.com/pediatric-sleep-medicine

Nocturnal sleep architecture in idiopathic hypersomnia: a systematic review and meta-analysis. November 2017 · Sleep Medicine ... on nocturnal polysomnographic sleep recordings in the diagnosis of central nervous system disorders of hypersomnolence, ... particularly idiopathic hypersomnia (IH). Objective Determine what differences in sleep staging and architecture exist between ...

https://www.researchgate.net/publication/7469424_An_Olfactory_Stimulus_Modifies_Nighttime_Sleep_in_Young_Men_and_Women

Hypersomnolence. Ritalin or other stimulant drugs have been used successfully in controlling the need to sleep during the day. ... Sometimes a mild diuretic will help reduce fluid retention but can worsen the edema of idiopathic cyclic edema. While one would ... Idiopathic hypersomnia is usually treated with stimulant medications such as amphetamine, methylphenidate, and modafinil. These ... "While others have envisioned a causal role for psychotropic drugs in idiopathic autism, we were astonished to find evidence ...

https://digitalnaturopath.com/treatments/conventional-drugs-information/

Differentially methylated positions associated with hypersomnolence, idiopathic hypersomnia, and long sleep time are provided ... Epigenetic Modification of Select Genes as Markers of Hypersomnolence ...

https://www.warf.org/search-results/?s_tech_category=diagnostics

... idiopathic hypersomnia, Kleine-Levin syndrome, and other central disorders of hypersomnolence, as defined in the International ... In ICSD-3, the names of some central disorders of hypersomnolence have been changed: narcolepsy with cataplexy and narcolepsy ...

https://flutrackers.com/forum/forum/welcome-to-the-scientific-library/other/780445-narcolepsy-and-other-central-hypersomnias

Alternatives to the multiple sleep latency test are needed for accurate diagnosis of idiopathic hypersomnia. This case ... Tags: case study, hypersomnolence, idiopathic hypersomnia, multiple sleep latency test (MSLT), polysomnography Share Facebook ... Moreover, idiopathic hypersomnia has fewer than two SOREMPs on PSG/MSLT, and CSF hypocretin-1 (when deficient, a marker of ... The phenotype of idiopathic hypersomnia includes "an almost endless need to sleep without feeling rested," she explains. Unlike ...

https://consultqd.clevelandclinic.org/case-study-extended-polysomnography-confirms-an-idiopathic-hypersomnia-diagnosis/

HYPERSOMNOLENCE, IDIOPATHIC. HIPERSONOLÊNCIA IDIOPÁTICA. HIPOVOLEMIA. HYPOVOLEMIA. HIPOVOLEMIA. HIPOXIA-ISQUEMIA DEL CEREBRO. ...

https://decs2011.bvsalud.org/E/news2000eip.htm

HYPERSOMNOLENCE, IDIOPATHIC. HIPERSONOLÊNCIA IDIOPÁTICA. HIPOVOLEMIA. HYPOVOLEMIA. HIPOVOLEMIA. HIPOXIA-ISQUEMIA DEL CEREBRO. ...

https://decs2016.bvsalud.org/E/news2000eip.htm

HYPERSOMNOLENCE, IDIOPATHIC. HIPERSONOLÊNCIA IDIOPÁTICA. HIPOVOLEMIA. HYPOVOLEMIA. HIPOVOLEMIA. HIPOXIA-ISQUEMIA DEL CEREBRO. ...

https://decs2019.bvsalud.org/E/news2000eip.htm